Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in acute ischemic stroke
2015-004783-11Phase 2Completed
- Sponsor
- Biogen
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Natalizumab with Placebo (2 arms). Primary endpoint: Composite global functional outcome at Day 90. Started Feb 2016; status: completed.
02
Drugs
natalizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2015-004783-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004783-11.